Anthropic reports early Claude results in drug development

On 27 October 2026 Anthropic published an update on its life sciences work. Over several months its scientists have worked with six organizations developing medicines: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group. Anthropic has also started drug discovery efforts of its own.

Results the partners reported

The figures below come from Anthropic’s post, which links to partner technical reports. They are not independently verified.

• Generate Biomedicines: Using Claude Code, scientists proposed new designs for part of a CAR T-cell therapy. One design was about 70% shorter than the standard version and, in lab tests, let immune cells make roughly 10 times as many receptors.
• Divergence Labs: Claude generated roughly 35,000 antibody designs in about a month for a food allergy approach. Early tests found three designs that bind IgE and 20 that dislodge it.
• BigHat Biosciences: The lab tested about 1,010 variants in about 10 weeks. The best versions bound more than 10x more tightly than the originals.
• Enveda: On 1,061 pages of manufacturing documents, Claude caught all 11 issues human reviewers had found and flagged seven more. Review time fell by 89%, from over 25 hours to less than three.

Anthropic also acquired Mithril Medicine, a one-person company working on two rare forms of muscular dystrophy. It says a candidate went from idea to promising results in mice in under 18 months, and that a drug could be ready for human trials as soon as late 2028 if candidates keep holding up.

Why it matters

This is our analysis. The results are self-reported by a vendor and its partners, and Anthropic itself says the work is still early and mostly preclinical, meaning it has not yet reached testing in people. The post is best read as a set of case studies on where AI may remove bottlenecks, such as paperwork and design iteration, rather than as evidence of new medicines.